Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
31 Oct 2024
31 Oct 2024
Historique:
received:
31
07
2024
accepted:
22
10
2024
revised:
18
10
2024
medline:
1
11
2024
pubmed:
1
11
2024
entrez:
1
11
2024
Statut:
epublish
Résumé
Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact of VTE among adolescents and young adult (AYA) patients (15-50 years) treated on Dana-Farber Cancer Institute (DFCI) ALL protocols. The 1- and 2-year cumulative incidence of VTE were 31.9% (95% CI: 27.0%, 36.9%) and 33.5% (95% CI: 28.5%, 38.5%) respectively, with most events occurring during ASP-based consolidation phase (68.6%). VTE was more frequent in patients with overweight/obese vs. normal BMI (39.2% vs. 29.0%, p = 0.048). In a 1-year landmark analysis, the 4-year overall survival was 91.5%, without difference between patients with vs. without VTE (93.8% vs. 90.0%, p = 0.93). Relapse and non-relapse mortality rates were also similar. Among patients treated at Dana-Farber/Harvard Cancer Center, cerebral sinus vein thrombosis occurred in 3.6% of patients (8.5% of VTE events) in comparison to pulmonary embolism (32.9%) and deep vein thromboses (58.6%, 24.4% line-associated). In a Cox regression model for VTE free-time, elevated BMI was associated with shorter VTE free-time (HR 1.94 [95% CI 1.13-3.35], p = 0.018), while low molecular weight heparin (LMWH) prophylaxis as time-varying covariate was not. In conclusion, we found that VTE was frequent in AYAs treated on DFCI ALL protocols but did not impact survival outcomes. Overweight/obese BMI increased risk for VTE.
Identifiants
pubmed: 39482298
doi: 10.1038/s41408-024-01178-5
pii: 10.1038/s41408-024-01178-5
doi:
Substances chimiques
Asparaginase
EC 3.5.1.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191Informations de copyright
© 2024. The Author(s).
Références
Deangelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–34.
doi: 10.1038/leu.2014.229
pubmed: 25079173
Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019;133:1548–59.
doi: 10.1182/blood-2018-10-881961
pubmed: 30658992
Ali U, Naveed M, Ullah A, Ali K, Shah SA, Fahad S, et al. L-asparaginase as a critical component to combat Acute Lymphoblastic Leukaemia (ALL): A novel approach to target ALL. Eur J Pharmacol. 2016;771:199–210.
doi: 10.1016/j.ejphar.2015.12.023
pubmed: 26698391
Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. Blood. 2020;135:987–95.
Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-Asparaginase treatment in adults with acute lymphoblastic leukaemia. Leukemia. 2013;27:553–9.
doi: 10.1038/leu.2012.290
pubmed: 23099335
Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011;152:452–9.
doi: 10.1111/j.1365-2141.2010.08524.x
pubmed: 21210774
Advani AS, Larsen E, Laumann K, Luger SM, Liedtke M, Devidas M, et al. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. Blood Adv. 2021;5:504–12.
doi: 10.1182/bloodadvances.2020002439
pubmed: 33496745
Rank CU, Toft N, Tuckuviene R, Grell K, Nielsen OJ, Frandsen TL, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131:2475–84.
doi: 10.1182/blood-2018-01-827949
pubmed: 29661787
Orvain C, Balsat M, Tavernier E, Marolleau J-P, Pabst T, Chevallier P, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136:328–38.
Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase‐based therapy. Br J Haematol. 2020;191:748–54.
doi: 10.1111/bjh.16695
pubmed: 32395867
Grace RF, DeAngelo DJ, Stevenson KE, Neuberg D, Sallan SE, Mourad YRA, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45:306–14.
doi: 10.1007/s11239-017-1597-7
pubmed: 29260426
Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, et al. Postinduction dexamethasone and individualized dosing of escherichia coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute. J Clin Oncol. 2013;31:1202–10.
doi: 10.1200/JCO.2012.43.2070
pubmed: 23358966
Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O’Brien JE, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16:1677–90.
doi: 10.1016/S1470-2045(15)00363-0
pubmed: 26549586
DeAngelo DJ, Stevenson K, Neuberg DS, Silverman LB, Ballen KK, Asch JD, et al. A multicenter phase II study using a dose intensified pegylated-asparaginase pediatric regimen in adults with untreated acute lymphoblastic leukemia: a DFCI ALL consortium trial. Blood. 2015;126:80.
doi: 10.1182/blood.V126.23.80.80
Aldoss I, Douer D, Behrendt CE, Chaudhary P, Mohrbacher A, Vrona J, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96:375–80.
doi: 10.1111/ejh.12600
pubmed: 26095294
Rytting ME, Thomas DA, O’Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, et al. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014;120:3660–8.
doi: 10.1002/cncr.28930
pubmed: 25042398
Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, et al. Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer. 2013;119:90–8.
doi: 10.1002/cncr.27617
pubmed: 22744771
Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, et al. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. Int J Hematol Oncol. 2020;9:Ijh28.
doi: 10.2217/ijh-2020-0009
pubmed: 33014332
Shimony S, Flamand Y, Valtis YK, Place AE, Silverman LB, Vrooman LM, et al. Effect of BMI on toxicities and survival among adolescents and young adults treated on DFCI Consortium ALL trials. Blood Adv. 2023;7:5234–45.
Valtis YK, Flamand Y, Shimony S, Place AE, Silverman LB, Vrooman LM, et al. Treatment completion, asparaginase completion, and oncologic outcomes among children, adolescents and young adults with acute lymphoblastic leukemia treated with DFCI Consortium Protocols. Leukemia. 2024;38:482–90.
doi: 10.1038/s41375-023-02115-4
pubmed: 38177437
Aldoss I, Yin J, Wall A, Mrózek K, Liedtke M, Claxton DF, et al. The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study. Blood Adv. 2023;7:196–204.
doi: 10.1182/bloodadvances.2022007791
pubmed: 36269846
Greiner J, Schrappe M, Claviez A, Zimmermann M, Niemeyer C, Kolb R, et al. THROMBOTECT—a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104:756–65.
doi: 10.3324/haematol.2018.194175
pubmed: 30262570
O’Brien SH, Rodriguez V, Lew G, Newburger JW, Schultz CL, Orgel E, et al. Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial. Lancet Haematol. 2024;11:e27–e37.
doi: 10.1016/S2352-3026(23)00314-9
pubmed: 37980924
Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res. 2010;125:220–3.
doi: 10.1016/j.thromres.2009.02.003
pubmed: 19272635